Back

Conditional CAR T cells with specificity to oncofetal glycosaminoglycans in solid tumors

Khazamipour, N.; Oo, H. Z.; Al-Nakouzi, N.; Marzban, M.; Khazamipour, N.; Robert, M. E.; Farivar, N.; Moskalev, I.; Lo, J.; Ghaidi, F.; Nelepcu, I.; Moeen, A.; Truong, S.; Dagil, R.; Choudhary, S.; Gustavsson, T.; Zhai, B.; Heitzender, S.; Salanti, A.; Sorensen, P. H.; Daugaard, M.

2024-06-02 cancer biology
10.1101/2024.05.29.596014 bioRxiv
Show abstract

Glycosaminoglycans are often deprioritized as targets for synthetic immunotherapy due to the complexity of glyco-epitopes and limited options for obtaining specific subtype-binding. Solid tumors express proteoglycans that are modified with oncofetal chondroitin sulfate (CS), a modification normally restricted to the placenta. Here, we report the design and functionality of conditional chimeric antigen receptor (CAR) T cells with selectivity to oncofetal CS. Following expression in T cells, the CAR could be armed with recombinant VAR2CSA lectins (rVAR2) to target tumor cells expressing oncofetal CS. While un-armed CAR T cells remained inactive in the presence of target cells, VAR2-armed CAR T cells displayed robust activation and the ability to eliminate diverse tumor cell types in vitro. Cytotoxicity of the CAR T cells was proportional to the concentration of rVAR2 available to the CAR, offering a potential molecular handle to finetune CAR T cell activity. In vivo, armed CAR T cells rapidly targeted bladder tumors and increased survival of tumor-bearing mice. Thus, our work indicates that cancer-restricted glycosaminoglycans can be exploited as potential targets for CAR T cell therapy.

Matching journals

The top 11 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.